Despite the increasing use of antivascular endothelial growth factors (anti-VEGF), photodynamic therapy (PDT) with Verteporfin® is still considered the gold standard treatment of subfoveal and juxtafoveal classic choroidal neovascularization (CNV).
Methods
Case report.
Results
The authors report a case of a 72-year-old man who developed choroidal nonperfusion and significant subretinal fluid formation with associated severe visual loss following PDT of predominantly classic juxtafoveal CNV.
Conclusions
Although reported separately, these two complications have not been previously reported to occur in association after PDT treatment of classic CNV and may represent exaggeration of normal events occurring after PDT.
BresslerN.M.Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: two year results of 2 randomized clinical trials–TAP report 2. Arch Ophthalmol2001; 119: 198–207.
2.
ArnoldJ.J., BlinderK.J., BresslerN.M.Acute severe visual acuity decrease after photodynamic therapy with verteporfin: case reports from randomized clinical trials–TAP and VIP Report No. 3. Am J Ophthalmol2004; 137: 683–96.
3.
Schmidt-ErfurthU., NiemeyerM., GeitzenauerW., MichelsS.Time course and morphology of vascular effects associated with photodynamic therapy. Ophthalmology2005; 112: 2061–9.
4.
IsolaV., PeceA., ParodiM.B.Choroidal ischemia after photodynamic therapy with verteporfin for choroidal neovascularization. Am J Ophthalmol2006; 142: 680–3.
